Persistent polyclonal B cell lymphocytosis (PPBL) is a rare lymphoproliferative disorder of unclear natural history and its potential for B cell malignancy remains unknown. We describe the case of a 39-year-old female who presented with stage IV-B large cell lymphoma 19 years after an initial diagnosis of PPBL; her disease was rapidly fatal despite intensive chemotherapy and blood stem cell transplantation. Because we had recently identified multiple bcl-2/lg gene rearrangements in blood mononuclear cells of patients with PPBL, we sought evidence of this oncogene in this particular patient: bcl-2/lg gene rearrangements were found in blood mononuclear cells but not in lymphoma cells. Owing to the possible role of Epstein-Barr virus (EBV) in the pathogenesis of PPBL, we also hypothesized our patient might have an EBV-related lymphoproliferative disorder. Despite serologies consistent with past exposure to this virus, it was not found in lymphoma cells using a sensitive polymerase chain reaction technique. We conclude that nonHodgkin's lymphoma may occur during the course of PPBL. However, longer follow-up in more patients will be needed in order to better clarify the risk of hematologic malignancy in patients with PPBL.
Introduction
Persistent polyclonal B cell lymphocytosis (PPBL) is a syndrome that was originally described in 1982. 1 It occurs almost exclusively in women 2 and is usually diagnosed in their second or third decade. Subjects with PPBL are most often identified after referral to the hematologist for evaluation of mild to moderate lymphocytosis. Clinically, the affected patients are either asymptomatic or have minor non-specific complaints such as fatigue or malaise; most, but not all, are cigarette smokers. [3] [4] [5] Physical examination is usually within normal limits except for mild splenomegaly in some cases, although the incidence of this finding increases with the use of radiologic imaging. Patients with PPBL are commonly misdiagnosed to have chronic lymphocytic leukemia (CLL) or non-Hodgkin's lymphoma (NHL) in leukemic phase, and some have even received chemotherapy before a clear diagnosis of PPBL is made. Although believed to be a rare entity, we have been identifying one to two new cases of PPBL per year at our institution, which suggests a higher prevalence than initially reported.
Laboratory investigation of patients with PPBL reveals the presence of polyclonal B cell lymphocytosis with otherwise normal hematologic parameters. Characteristic binucleated cells are found in variable numbers on careful blood smear examination. In addition, all patients have increased levels of Correspondence: J Roy, CHA, Pavillon Saint-Sacrement, 1050 chemin Sainte-Foy, Québec (Qc), Canada G1S 4L8; Fax: 418 682 7961 Received 22 September 1997; accepted 12 February 1998 immunoglobulin (Ig) M with a polyclonal pattern on protein electropheresis. Flow cytometry cell analysis displays the presence of the CD19 antigen and surface IgM with a normal kappa/lambda ratio. In contrast to CLL, CD5 is absent. There is an association between HLA-DR 7 and PPBL in more than two-thirds of the patients but the reason for such an association remains unclear. 3, 6 There has been one report of PPBL occurring in identical female twins. 7 No other obvious genetic predisposition or familial inheritance has yet been described and there is no consistent chromosomal abnormality reported in these patients.
To date, the pathogenesis of PPBL remains undetermined. The presence of binucleated cells, the accumulation of mature-looking B lymphocytes over time and the indolent course of PPBL are characteristics reminiscent of low-grade lymphomas in leukemic phase and prompted us to explore the role of the bcl-2 oncogene in this condition. Bcl-2 is particularly important in lymphoid malignancies: 85% of follicular and approximately 20% of large cell lymphomas have a translocation which juxtaposes the bcl-2 gene of chromosome 18 to the Ig gene locus located on chromosome 14. 8, 9 This t(14;18) results in the overexpression of the bcl-2 protein with consequently the accumulation of clonal B cells by inhibition of apoptosis or programmed cell death. 10, 11 Using a polymerase chain reaction (PCR) assay targeting the usual breakpoint regions of the t(14;18), 12 we recently performed an analysis of the bcl-2/lg gene rearrangements on DNA isolated from peripheral blood mononuclear cells (PBMC) obtained from six patients with PPBL diagnosed at our institution between 1975 and 1994. 13 Interestingly, we found that the bcl-2/lg gene was rearranged in all six patients, with multiple rearrangements in five of them. 13 Sequence analysis confirmed the specificity of the fragments for the bcl-2/lg translocation and the presence of multiple rearrangements in all but one patient. Since the publication of these results, five additional patients have been studied with similar findings. 14 Bcl-2 protein expression by Western blot analysis was also increased in all patients studied. Our data suggest that inhibition of apoptosis might well be the underlying mechanism leading to B cell accumulation in patients with PPBL. Identifying bcl-2/lg gene rearrangements in patients with PPBL is also of practical relevance for the clinician because this finding further increases the risk of confusion with other patients having low-grade NHL in leukemic phase.
The exact mechanisms leading to bcl-2/lg gene rearrangement in PPBL remain uncertain at the present time, but chronic viral infection has been suggested as a possible contributing event. Of note, it has been previously shown that the latent membrane protein (LMP)-1 gene of the Epstein-Barr virus (EBV) can induce bcl-2 expression. 15 Other findings incriminating EBV include reports in which viral DNA has been amplified by PCR and identified in lymphoid cells obtained from two patients with PPBL using in situ hybridiz-ation. 16, 17 An EBV-positive line has also been established from another patient with PPBL. 18 The potential for malignancy in PPBL remains unknown. Until now, only one case of neoplasia occurring in a patient with PPBL has been reported. Lawlor and colleagues 19 have indeed described a case of pulmonary blastoma, a rare malignant tumor of combined mesenchymal and epithelial origin. The ultrastructural study of the lymphocytes using electron microscopy 20 and the presence of bcl-2/lg gene rearrangement are findings supporting the hypothesis that PPBL might in fact be a pre-malignant disorder of the B cell population. We report the first case of large cell lymphoma in a patient with PPBL and describe the molecular features associated with the tumor.
History
In 1975, a 20-year-old female smoker was referred to our institution for lymphocytosis of unclear etiology. At that time, clinical findings included intermittent fatigue and a barely palpable spleen on physical examination. The initial complete blood count was only remarkable for 25.8 × 10 9 /l leukocytes, of which 51% were mature lymphocytes with several showing characteristic binucleated nuclei; bone marrow aspirate was normal. An ultrasound of the abdomen revealed isolated mild splenomegaly. Cell surface marker analyses performed on multiple occasions over the following years revealed the presence of polyclonal B cell lymphocytosis (B cells ranging from 5.3 to 12.2 × 10 9 /l with normal kappa/lambda ratio) with positive surface IgM. HLA-typing revealed the patient was positive for the HLA-DR 6 and 7 antigens. In addition, Southern blot and PCR analysis of the heavy chain Ig gene performed on blood mononuclear cells in 1991 confirmed the B cell proliferation was polyclonal. The patient remained clinically stable until 1991 when she was lost to follow-up.
In November 1994, the patient consulted for left-sided pleuritic chest pain. She also complained at that time of night sweats, anorexia and a 6-kg weight loss. Vital signs were normal except for hyperthermia at 38.7°C. There were no palpable nodes, but the spleen was then enlarged at 4 cm below costal margin. Laboratory examinations revealed a leukocyte count of 8.2 × 10 9 /l with 49% lymphocytes, a hemoglobin of 81 g/l with features of anemia of chronic disease and normal platelets. The sedimentation rate was much increased at 138 mm. Multiple rouleaux and typical binucleated lymphocytes were identified on blood smear (Figure 1 ). The LDH was increased at 596 U/l (normal Ͻ334 U/l). The total IgM level was increased at 21.4 g/l (normal Ͻ2.0 g/l) with monoclonal IgM on immunofixation and slightly decreased IgA and IgG levels. On bone marrow biopsy, there was trilineage hyperplasia with two small paratrabecular lymphomatous aggregates. EBV serology was consistent with past exposure to the virus with IgG anti-VCA and anti-EBNA titers of 1/2000 and 1/80, respectively.
A chest X-ray showed mediastinal enlargement with bilateral basal pulmonary lesions. There were several 3 cm nodes in the anterior mediastinum and a 10 × 20 cm mass adhering to the left pericardium on chest computer tomographic (CT) scan. An echocardiogram revealed the presence of a moderate pericardial effusion without signs of tamponade. The abdomen CT scan showed splenomegaly, hepatomegaly, a mass infiltrating the left kidney and a few enlarged retroperitoneal nodes. A bone scan was normal.
A lymph node biopsy through mediastinoscopy was perfor-
Figure 1
Shown is a typical binucleated cell found in patients with persistent polyclonal B cell lymphocytosis (May-Grü nwald-Giemsa, ×1000).
med and histologic examination revealed the presence of a large cell lymphoma. The lymph node showed partial diffuse infiltration by a population of monomorphic large cells with round nuclei containing three to five small peripheral nucleoli and a moderate amount of basophilic cytoplasm. The large non-cleaved centrofollicular cells were accompanied by few immunoblasts characterized by nuclei with a prominent nucleolus. Mitoses were numerous (Figure 2) .
The patient received three cycles of cyclophosphamide, adriamycin, vincristine and prednisone (CHOP), but fever and night sweats recurred shortly after: a control CT showed partial response. The patient then received salvage chemotherapy with etoposide, methylprednisolone, Ara-C and cisplatin (ESHAP) and two cycles of vincristine, prednisone, etoposide and mitoxantrone, after which the CT scan showed significant reduction of the lung lesions but progressive disease in the left kidney. Despite overall sub-optimal response, the patient underwent autologous blood stem cell transplantation after a conditioning regimen consisting of high-dose cyclophosphamide, etoposide and carmustine. The post-transplant course was uneventful with prompt engraftment. However, B symptoms reappeared on day +25 and the patient died on day +47 from progressive disease.
At autopsy, an 8 × 12 cm mediastinal lymphomatous mass was found with direct extension to the ascending aorta, the superior vena cava, the trachea, both lungs, the pericardium, the left cardiac atrium and the left parietal pleura. In addition, there was extensive involvement of the splenic, peri-hepatic, and retroperitoneal lymph nodes with contiguous infiltration of the left kidney and adrenal gland. Finally, there was also massive involvement of the liver and the spleen (weights of 2610 g and 1460 g, respectively).
Materials and methods

Tissue samples
All blood and tumor samples were obtained after informed consent. PBMC were isolated by centrifugation over FicollHypaque (Pharmacia, Piscataway, NJ, USA) from our patient in 1991 and in 1994 (prior to chemotherapy) and from normal healthy volunteers. Tumor samples were collected at lymphoma presentation and autopsy and stored in liquid nitrogen.
Immunohistochemistry
Immunohistochemical studies were done using a modification of the avidin-biotin-peroxydase complex (ABC) method. 21 Monoclonal antibodies against CD20 (Dako, Carpinteria, CA, USA), CD45RO (Dako), CD74 (Clonab, Denville, NJ, USA), and Bcl-2 antigens (Dako) were used at a dilution of 1/100, 1/100, 1/50, and 1/400, respectively. Kappa and lambda light chains polyclonal antibodies (both Dako) were used at a dilution of 1/500.
PCR Studies
Bcl-2/lg gene rearrangement analysis was performed after DNA extraction from PBMC or tumor samples using standard procedures and a PCR technique described by Gribben et al. 12 Briefly, 1 g of DNA was used for each PCR analysis. The first round of amplification of 25 cycles was performed using either bcl-2-specific primers 5ЈCAGCCTTGAAACATT-GATGG3Ј for the major breakpoint region (MBR) or 5ЈCGTGCTGGTACCACTCCTG3Ј for the minor cluster region (mcr) in combination with the Ig heavy chain JH primer 5ЈACCTGAGGAGACGGTGACC3Ј. For the second round of amplication of 30 cycles, 5 l of the first PCR product was used in the presence of the MBR primer 5ЈTATGGTGGTTTGACCTTTAG3Ј or the mcr primer 5ЈGGACCTTCCTTGGTGTGTTG3Ј and of the JH primer 5ЈACCAGGGTCCCTTGGCCCCA3Ј. Cells of the H-2 cell line (kindly provided by Dr JG Gribben, Dana-Farber Cancer Institute, Boston, MA, USA) and PBMC from healthy volunteers were used as positive and negative controls, respectively. All PCR products in this report were further characterized by agarose gel electrophoresis, and each sample was analyzed at least three times. In addition, a control containing all PCR reagents and water was included in all experiments.
Evaluation of clonality was assessed by PCR analysis of the chain determining region 3 (CDR3) of the human Ig heavy chain gene according to a modified technique described by Brisco et al. 22 After RNA extraction and reverse transcription of either Raji cells (ATCC, Rockville, MD, USA), lymphoma cells or PBMC from normal subjects, cDNA was amplified with the FR3A primer 5ЈACACGGC(C/T)(G/C)TGTATTA-CTGT3Ј and the Ig VLJH primer 5ЈGTGACCAGGGT/ NCCTTGGCCCCAG3Ј for 40 cycles. RNA extraction quality control was assessed using glucose 3-phosphate dehydrogenase (G3PDH) primers 5ЈTGAAGGTCGGAGTCAACGGA-TTTGGT3Ј and 5ЈCATGTGGGCCATGAGGTCCACCAC3Ј with the same amplification conditions. Epstein-Barr nuclear antigen-1 (EBNA-1) gene analysis was done according to the technique described by Finke et al. 23 After RNA extraction of Raji cells (positive control), PBMC from normal subjects (negative control) or lymphoma cells, cDNA obtained after reverse transcription was amplified for 30 cycles using EBNA-1 5ЈAGCGATAGAGCAGGGCCC-CGCAGA3Ј and 5ЈCAAAACCTCAGCAAATATATGAGT3Ј primers. One microliter of the first amplification product was used for the second round of amplification with 5ЈTCAGGGTGATGGAGGCA3Ј and 5ЈACAATGGACTCC-CTTAGC3Ј oligonucleotides.
Results
The lymphoma cells both from the initial lymph node biopsy and autopsy specimens revealed a B cell phenotype, with CD20 and CD74 surface antigens expression and cytoplasmic lambda light chain restriction. In contrast, the cells were negative for the pan T cell antigen CD45RO. Cell monoclonality of tumor samples was confirmed by PCR analysis of the CDR3 of the human Ig heavy chain gene (Figure 3) . The same analysis was performed on the patient's PBMC at presentation prior to chemotherapy but no monoclonal population was identified.
In this particular patient, we had previously found the presence in PBMC of two bcl-2/lg gene rearrangements in 1991. 13 We then sought evidence of bcl-2 rearrangements in blood and tumor cells in order to verify whether this lymphoma was arising from a bcl-2 translocated clone or not. Two rearrangements in the MBR of the bcl-2 gene were again identified in PBMC collected on admission prior to chemotherapy ( Figure  3) . No evidence of bcl-2/lg gene rearrangement was found in lymphoma cells using our PCR analysis. In addition, immunoperoxidase staining did not reveal Bcl-2 protein upregulation (data not shown).
EBV is a well-known agent involved in the pathogenesis of endemic Burkitt's lymphoma and NHL in immunocompromised patients. Because EBV has also been identified in cells of patients with PPBL, 16, 17 we hypothesized that our patient might have an EBV-related lymphoma. Several genes are believed to play a critical role for the immortalizing function of EBV; of these, EBNA-1 is essential for viral replication and always expressed in NHL associated with EBV. 23 Despite adequate RNA extraction, no EBNA-1 signal could be identified in lymphoma cells of this patient (Figure 3) .
Discussion
PPBL is a rare disorder of unknown etiology and unclear natural history The stability of B cell proliferation over time, a polyclonal cell population and the usually indolent overall clinical course of these patients suggest that PPBL is a benign condition. The emergence of a clonal population in some patients 24 and our reported case of B cell NHL associated with a monoclonal serum IgM raise, however, the possibility that PPBL may potentially evolve toward an aggressive lymphoma.
In addition, our recent observation of multiple bcl-2/lg gene rearrangements in all patients studied with PPBL further suggests that PPBL might in fact be a pre-malignant condition. 13 The absence of bcl-2/lg gene rearrangement in this particular NHL indicates that the tumor did not arise from a previously translocated clone, thus suggesting an unrelated event. Nevertheless, it is possible that B cell accumulation over time might increase the risk of other subsequent illegitimate recombinations and favor the development of a B cell malignancy.
Owing to the possible role of EBV in the pathogenesis of PPBL, we investigated the possibility that our patient with stage IV-B NHL might have an EBV-related lymphoproliferative disorder but EBNA-1 mRNA could not be identified in tumor cells using a sensitive PCR analysis. Although our results indicate this lymphoma was not EBV-induced, they do not exclude a possible role for EBV in the pathogenesis of PPBL. Using a reverse transcriptase PCR assay, we have recently shown that EBNA-1 was expressed in all seven tested patients with PPBL while only one of seven normal controls was positive. 25 Similarly, a specific fragment of the LMP-1 gene was present in all seven PPBL patients but undetected in PBMC of normal subjects. Our recent data and others [16] [17] [18] strongly support the presence of a latent EBV infection in patients with PPBL. HLA-DR7, present in most PPBL patients, might potentially play a role in facilitating viral infection. This antigen has been associated with a higher incidence of chronic persistent hepatitis B and unresponsiveness to hepatitis B vaccines, perhaps indicating that the HLA-DR7 phenotype is associated with an inadequate immune response against this virus and possibly others as well. 26, 27 In summary, we describe the first case of malignant lymphoma occurring in a patient with PPBL but our molecular analyses do not suggest that bcl-2 or EBV are directly involved in lymphoma genesis. Whether patients with PPBL are indeed at increased risk of hematologic malignancy remains unclear at the present time and will require longer follow-up in more patients. Meanwhile, we believe it is mandatory to follow these patients prospectively and report all cases of lymphoid malignancies.
